Shifting the paradigm in radiation safety.

Mohan Doss
Author Information
  1. Mohan Doss: Fox Chase Cancer Center.

Abstract

The current radiation safety paradigm using the linear no-threshold (LNT) model is based on the premise that even the smallest amount of radiation may cause mutations increasing the risk of cancer. Autopsy studies have shown that the presence of cancer cells is not a decisive factor in the occurrence of clinical cancer. On the other hand, suppression of immune system more than doubles the cancer risk in organ transplant patients, indicating its key role in keeping occult cancers in check. Low dose radiation (LDR) elevates immune response, and so it may reduce rather than increase the risk of cancer. LNT model pays exclusive attention to DNA damage, which is not a decisive factor, and completely ignores immune system response, which is an important factor, and so is not scientifically justifiable. By not recognizing the importance of the immune system in cancer, and not exploring exercise intervention, the current paradigm may have missed an opportunity to reduce cancer deaths among atomic bomb survivors. Increased antioxidants from LDR may reduce aging-related non-cancer diseases since oxidative damage is implicated in these. A paradigm shift is warranted to reduce further casualties, reduce fear of LDR, and enable investigation of potential beneficial applications of LDR.

Keywords

References

  1. Nature. 2007 Dec 6;450(7171):903-7 [PMID: 18026089]
  2. Pathol Int. 1997 May;47(5):293-300 [PMID: 9143024]
  3. Health Phys. 2009 Nov;97(5):493-504 [PMID: 19820459]
  4. Oncologist. 2007 Jul;12(7):864-72 [PMID: 17673617]
  5. Proc R Soc Med. 1970 Oct;63(10):1077-80 [PMID: 4320709]
  6. Ann ICRP. 2007;37(2-4):1-332 [PMID: 18082557]
  7. CMAJ. 2006 Mar 14;174(6):801-9 [PMID: 16534088]
  8. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1276-83 [PMID: 20406960]
  9. Int J Radiat Biol. 2008 Jan;84(1):1-14 [PMID: 17852558]
  10. Dose Response. 2011;9(4):444-64 [PMID: 22461755]
  11. Radiat Res. 1999 Jun;151(6):717-24 [PMID: 10360792]
  12. JAMA. 2011 Jun 22;305(24):2548-55 [PMID: 21693743]
  13. Radiat Res. 2009 Jan;171(1):1-8 [PMID: 19138046]
  14. Calif Med. 1949 Mar;70(3):189-93 [PMID: 18112454]
  15. Am J Pathol. 1979 Dec;97(3):456-72 [PMID: 389062]
  16. Physiol Chem Phys Med NMR. 1996;28(1):1-5 [PMID: 8875802]
  17. Neuropharmacology. 2010 Sep-Oct;59(4-5):290-4 [PMID: 20394761]
  18. J Appl Physiol (1985). 2001 Mar;90(3):1031-5 [PMID: 11181616]
  19. J Immunol. 1965 May;94:715-22 [PMID: 14296292]
  20. J Natl Cancer Inst. 2010 May 5;102(9):605-13 [PMID: 20413742]
  21. Hum Exp Toxicol. 2010 Apr;29(4):263-70 [PMID: 20332170]
  22. Rheumatol Int. 2005 Apr;25(3):205-10 [PMID: 14673618]
  23. J Natl Cancer Inst. 2007 May 16;99(10):754-64 [PMID: 17505071]
  24. Trends Pharmacol Sci. 2011 Mar;32(3):125-30 [PMID: 21216018]
  25. Yale J Biol Med. 1981 Nov-Dec;54(6):471-84 [PMID: 7342492]
  26. Radiat Res. 2011 Sep;176(3):356-65 [PMID: 21718105]
  27. Dose Response. 2009;7(1):52-89 [PMID: 19343116]
  28. J Radiat Res. 2007 Nov;48(6):455-60 [PMID: 17785936]
  29. Dose Response. 2010 Jan 28;8(2):148-71 [PMID: 20585443]
  30. Annu Rev Immunol. 2011;29:111-38 [PMID: 21166538]
  31. Br J Radiol. 2005 Jan;78(925):3-7 [PMID: 15673519]
  32. J Natl Cancer Inst. 2008 Jun 4;100(11):773-83 [PMID: 18505970]
  33. Chin Med J (Engl). 2004 Jul;117(7):1036-9 [PMID: 15265378]
  34. Int J Cancer. 2009 Oct 15;125(8):1747-54 [PMID: 19444916]
  35. Expert Rev Anticancer Ther. 2011 May;11(5):791-802 [PMID: 21554054]
  36. Health Phys. 2007 Feb;92(2):157-69 [PMID: 17220717]
  37. Dose Response. 2008;6(4):333-51 [PMID: 19088900]
  38. Radiat Environ Biophys. 2006 Mar;44(4):253-6 [PMID: 16470411]
  39. Proc Natl Acad Sci U S A. 2009 May 26;106(21):8665-70 [PMID: 19433800]
  40. Vet Med (Praha). 1990 Aug;35(8):495-500 [PMID: 2102584]
  41. J Radiat Res. 2003 Jun;44(2):95-9 [PMID: 13678337]
  42. Int J Radiat Biol. 2005 Oct;81(10):731-40 [PMID: 16449080]
  43. Eur Urol. 2005 Nov;48(5):739-44 [PMID: 16203079]
  44. Hematol Oncol Clin North Am. 2011 Aug;25(4):893-915 [PMID: 21763973]
  45. JAMA. 2007 Feb 28;297(8):842-57 [PMID: 17327526]
  46. J Radiol Prot. 2003 Sep;23(3):263-8 [PMID: 14582718]
  47. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):379-86 [PMID: 18250341]
  48. AJR Am J Roentgenol. 2002 Nov;179(5):1137-43 [PMID: 12388487]
  49. Dermatology. 2008;217(1):38-44 [PMID: 18367839]
  50. Dose Response. 2010 Sep 10;8(4):534-42 [PMID: 21191490]
  51. Environ Health Perspect. 2006 Nov;114(11):1631-5 [PMID: 17107845]
  52. Mol Interv. 2007 Jun;7(3):147-56 [PMID: 17609521]
  53. Radiat Res. 2010 Jul;174(1):46-51 [PMID: 20681798]
  54. Circulation. 2004 Aug 3;110(5):637-41 [PMID: 15289389]
  55. J Clin Oncol. 2011 Feb 20;29(6):726-32 [PMID: 21205749]
  56. J Radiat Res. 2007 Mar;48(2):113-20 [PMID: 17339750]
  57. Curr Pharm Biotechnol. 2011 Feb 1;12(2):182-8 [PMID: 21044009]
  58. Ann N Y Acad Sci. 2002 Apr;959:82-92 [PMID: 11976188]
  59. Radiat Res. 2011 May;175(5):665-76 [PMID: 21375359]
  60. BMJ. 2010 Nov 04;341:c5702 [PMID: 21051774]
  61. Allergy. 2005 Sep;60(9):1098-111 [PMID: 16076292]
  62. Int J Radiat Biol. 2008 Mar;84(3):201-10 [PMID: 18300020]
  63. J Natl Med Assoc. 2011 Aug;103(8):695-700 [PMID: 22046846]
  64. Cancer Res. 2007 Feb 1;67(3):1246-53 [PMID: 17283161]
  65. Free Radic Biol Med. 1991;11(3):299-306 [PMID: 1937147]
  66. FASEB J. 1995 Sep;9(12):1173-82 [PMID: 7672510]
  67. Med Phys. 1998 Mar;25(3):291-9; discussion 300 [PMID: 9547496]
  68. Ageing Res Rev. 2008 Jan;7(1):34-42 [PMID: 17869589]
  69. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19447-8 [PMID: 22109550]
  70. Psychol Rep. 1965 Feb;16:127-32 [PMID: 14283948]
  71. Free Radic Biol Med. 1999 Feb;26(3-4):388-95 [PMID: 9895231]
  72. Dose Response. 2006 Aug 28;5(1):39-47 [PMID: 18648611]
  73. Radiology. 2009 Apr;251(1):6-12 [PMID: 19332841]
  74. Radiology. 2009 Apr;251(1):13-22 [PMID: 19332842]
  75. Radiat Res. 2011 Mar;175(3):307-21 [PMID: 21388274]
  76. BMJ. 2002 Jul 27;325(7357):185 [PMID: 12142304]
  77. Radiat Environ Biophys. 2000 Mar;39(1):17-24 [PMID: 10789891]
  78. Radiat Res. 1972 Jun;50(3):699-707 [PMID: 5030092]
  79. Science. 1952 Aug 15;116(3007):169-71 [PMID: 14950226]
  80. Immunol Cell Biol. 2000 Oct;78(5):483-4 [PMID: 11050530]
  81. Radiat Res. 1979 Nov;80(2):317-24 [PMID: 504578]
  82. Curr Sports Med Rep. 2003 Oct;2(5):239-42 [PMID: 12959703]
  83. Clin Infect Dis. 2008 Apr 1;46(7):1078-84 [PMID: 18444828]
  84. Health Phys. 1983 Mar;44(3):207-19 [PMID: 6832973]
  85. Australas Phys Eng Sci Med. 1997 Sep;20(3):125-38 [PMID: 9409013]
  86. Exerc Sport Sci Rev. 2009 Oct;37(4):157-64 [PMID: 19955864]
  87. Nonlinearity Biol Toxicol Med. 2004 Oct;2(4):293-316 [PMID: 19330149]
  88. Dose Response. 2007 Sep 10;5(4):284-91 [PMID: 18648562]
  89. Dose Response. 2008;6(4):369-82 [PMID: 19088902]
  90. Circulation. 2001 Nov 27;104(22):2673-8 [PMID: 11723017]
  91. Recenti Prog Med. 2011 Oct;102(10):399-406 [PMID: 21989400]
  92. Curr Oncol Rep. 2011 Feb;13(1):71-6 [PMID: 21080117]
  93. S Afr Med J. 1983 Oct 1;64(15):582-4 [PMID: 6623247]
  94. Lancet. 1973 Jul 14;2(7820):55-7 [PMID: 4123616]
  95. Free Radic Biol Med. 2011 Sep 1;51(5):993-9 [PMID: 21163347]
  96. Calcif Tissue Int. 2010 Sep;87(3):226-35 [PMID: 20614110]
  97. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):317-9 [PMID: 16168825]
  98. Med Phys. 2002 Jul;29(7):1511-2 [PMID: 12148732]
  99. Neurosci Lett. 2001 May 25;304(3):157-60 [PMID: 11343826]
  100. Annu Rev Immunol. 2004;22:329-60 [PMID: 15032581]
  101. Radiat Res. 2005 Feb;163(2):153-8 [PMID: 15658890]
  102. Int J Cancer. 2003 Jan 1;103(1):97-100 [PMID: 12455059]
  103. Curr Opin HIV AIDS. 2009 Jan;4(1):35-41 [PMID: 19343829]
  104. Am J Ther. 2011 May;18(3):266-78 [PMID: 19797943]
  105. J Neurochem. 1986 Apr;46(4):1042-5 [PMID: 3950618]
  106. Appl Physiol Nutr Metab. 2011 Feb;36(1):80-7 [PMID: 21326381]
  107. Eur J Clin Invest. 2011 Dec;41(12):1318-22 [PMID: 21623777]
  108. Radiat Res. 2006 Mar;165(3):337-42 [PMID: 16494522]
  109. Hum Exp Toxicol. 2008 Feb;27(2):135-42 [PMID: 18480138]
  110. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1595-601 [PMID: 20501761]
  111. Nonlinearity Biol Toxicol Med. 2003 Jan;1(1):71-92 [PMID: 19330113]
  112. Br J Radiol. 2005 Jan;78(925):14-6 [PMID: 15673522]
  113. Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1038-47 [PMID: 20061549]
  114. Am J Pathol. 1999 May;154(5):1423-9 [PMID: 10329595]
  115. Hypertension. 2009 Dec;54(6):1206-8 [PMID: 19841287]
  116. Int J Rheum Dis. 2009 Apr;12(1):29-33 [PMID: 20374313]
  117. Free Radic Biol Med. 2010 Nov 15;49(9):1417-21 [PMID: 20692334]
  118. Nat Rev Immunol. 2009 May;9(5):377-84 [PMID: 19330016]
  119. Radiat Res. 2003 Oct;160(4):381-407 [PMID: 12968934]
  120. Dose Response. 2009 Dec 10;8(2):209-26 [PMID: 20585439]
  121. Arch Toxicol. 2009 Mar;83(3):203-25 [PMID: 19247635]
  122. Br J Cancer. 2011 Dec 6;105 Suppl 2:S77-81 [PMID: 22158327]
  123. J Radiat Res. 2008 Jul;49(4):381-9 [PMID: 18413978]

Word Cloud

Created with Highcharts 10.0.0cancerradiationreduceparadigmmayimmunesystemLDRsafetyLNTmodelriskfactorcurrentdecisiveLowdoseresponsedamagediseasesusinglinearno-thresholdbasedpremiseevensmallestamountcausemutationsincreasingAutopsystudiesshownpresencecellsoccurrenceclinicalhandsuppressiondoublesorgantransplantpatientsindicatingkeyrolekeepingoccultcancerscheckelevatesratherincreasepaysexclusiveattentionDNAcompletelyignoresimportantscientificallyjustifiablerecognizingimportanceexploringexerciseinterventionmissedopportunitydeathsamongatomicbombsurvivorsIncreasedantioxidantsaging-relatednon-cancersinceoxidativeimplicatedshiftwarrantedcasualtiesfearenableinvestigationpotentialbeneficialapplicationsShiftingAging-relatedAntioxidantstimulationImmuneRadiation

Similar Articles

Cited By